Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCS PICKS CALIFORNIA PHARMACISTS ASSOCIATION's JOHNSON AS NEW TOP EXEC

Executive Summary

PCS PICKS CALIFORNIA PHARMACISTS ASSOCIATION's JOHNSON AS NEW TOP EXEC beginning in February. Johnson's resignation as executive VP of the California Pharmacists Association after 20 years becomes effective immediately after the association's annual meeting in Sacramento. The presidency of the Pharmaceutical Card Service has been filled on an acting basis by parent company McKesson's Chairman Alan Seelenfreund and his predecessor Thomas Field since Donald Dahlin vacated the post last summer to join Medco. Johnson is reportedly considering bringing two CPhA officials with him to PCS: John Skahl and Robert Abrams. Skahl is executive VP of the association's Pharmaceutical Care Network buying group subsidiary. Abrams, a former executive with PAID Prescriptions, Medco's prescription drug claims processing business, joined PCN earlier this year ("The Pink Sheet" Jan. 2, "In Brief"). McKesson is one of the original wholesalers to participate in the PCN program. In selecting a pharmacy leader to head PCS, McKesson is making a strong move to modify organized pharmacy and assure its representation in corporate decisions. PCS recently angered at least one pharmacy association, NARD, when a PCS advertisement proclaimed its support of the profession despite market "pressures" that have forced the firm to discount AWP-based prescription drug reimbursements. NARD criticized the ad's attempt to "explain away" the confiscation of "pharmacists' earned discounts" ("The Pink Sheet" Aug. 7, p. 14). Before hiring Johnson, McKesson had considered divesting its 86% stake in PCS. As part of that review, McKesson reportedly discussed a wide range of affiliations with three national associations: NARD, the National Association of Chain Drug Stores and the American Pharmaceutical Association ("The Pink Sheet" Dec. 11, p. 18). The potential impact on PCS of Johnson's history as a pharmacy advocate remains to be seen. Observers within the profession are hoping that he will stress pharmacists' personal services over price cuts in developing a strategy for competing with mail-order pharmacies for health plans offering prescription drug benefits. Johnson and CPhA recently were among the cosponsors of a position paper, "California Pharmacy Plan for the 1990s," which urges that for all patients, pharmacists should provide medication profiles and personal counseling and take direct responsibility for drug therapy outcomes.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel